CSBR - Champions Oncology Inc Stock Price, Fair Value and News

5.06USD-0.01 (-0.20%)Delayed

Market Summary

USD5.06-0.01

Delayed

-0.20%

CSBR Stock Price

View Fullscreen

CSBR RSI Chart

CSBR Valuation

Market Cap

68.8M

Price/Earnings (Trailing)

-7.07

Price/Sales (Trailing)

1.4

EV/EBITDA

-8.39

Price/Free Cashflow

-10.24

CSBR Price/Sales (Trailing)

CSBR Profitability

EBT Margin

-19.62%

Return on Equity

472.69%

Return on Assets

-36.32%

Free Cashflow Yield

-9.77%

CSBR Fundamentals

CSBR Revenue

Revenue (TTM)

49.2M

Rev. Growth (Yr)

-5.9%

Rev. Growth (Qtr)

3.85%

CSBR Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

-3.73%

Earnings Growth (Qtr)

-22.16%

Breaking Down CSBR Revenue

Last 7 days

Last 30 days

-7.3%

Last 90 days

-23.5%

Trailing 12 Months

-0.8%

How does CSBR drawdown profile look like?

CSBR Financial Health

Current Ratio

0.6

CSBR Investor Care

Shares Dilution (1Y)

0.26%

Diluted EPS (TTM)

-0.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	49.2M	0	0	0
2023	53.7M	53.9M	52.7M	50.0M
2022	46.8M	49.1M	51.6M	54.1M
2021	39.2M	41.0M	42.7M	44.4M
2020	31.1M	32.1M	34.9M	37.4M
2019	24.3M	27.1M	27.6M	28.5M
2018	19.0M	20.2M	21.4M	22.9M
2017	14.5M	15.4M	16.8M	17.5M
2016	11.6M	11.2M	12.0M	13.5M
2015	8.1M	8.9M	9.8M	10.9M
2014	10.9M	11.6M	10.4M	9.9M
2013	7.9M	8.3M	9.2M	10.2M
2012	7.3M	7.2M	7.6M	7.3M
2011	0	6.9M	6.9M	7.7M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Champions Oncology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 12, 2024	mendelson daniel newman	bought	6,500	6.5	1,000	-
Jan 11, 2024	mendelson daniel newman	bought	12,540	6.27	2,000	-
Jan 10, 2024	mendelson daniel newman	bought	18,576	6.31	2,944	-
Jan 09, 2024	mendelson daniel newman	bought	18,750	6.25	3,000	-
Jan 08, 2024	mendelson daniel newman	bought	6,150	6.15	1,000	-
Jan 05, 2024	mendelson daniel newman	bought	12,180	6.09	2,000	-
Jan 04, 2024	mendelson daniel newman	bought	18,360	6.12	3,000	-
Jan 03, 2024	mendelson daniel newman	bought	2,915	5.83	500	-
Dec 21, 2023	mendelson daniel newman	bought	12,300	4.92	2,500	-
Dec 20, 2023	mendelson daniel newman	bought	10,122	4.82	2,100	-

Which funds bought or sold CSBR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	20.61	39,032	465,535	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-208,159	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	added	33.8	11,135	79,132	-%
Feb 14, 2024	Royal Bank of Canada	added	714	1,000	1,000	-%
Feb 14, 2024	NEA Management Company, LLC	unchanged	-	-1,011,270	9,630,940	0.64%
Feb 14, 2024	Battery Management Corp.	unchanged	-	-1,429,030	13,609,600	2.43%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-15,265	145,139	-%
Feb 14, 2024	AMERIPRISE FINANCIAL INC	reduced	-10.75	-116,611	406,409	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-21,508	143,652	-%
Feb 13, 2024	BlackRock Inc.	reduced	-0.17	-69,750	652,454	-%

Are Funds Buying or Selling CSBR?

Are funds buying CSBR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CSBR

No. of Funds

Unveiling Champions Oncology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	tocqueville asset management l.p.	5.0%	684,578	SC 13G
Feb 14, 2022	west elk partners, lp	8.09%	1,093,387	SC 13G/A
Jul 23, 2021	west elk partners, lp	5.06%	676,944	SC 13G

Recent SEC filings of Champions Oncology Inc

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	4	Insider Trading
Mar 15, 2024	10-Q	Quarterly Report
Mar 12, 2024	8-K	Current Report
Feb 12, 2024	SC 13G	Major Ownership Report
Jan 16, 2024	4	Insider Trading

Peers (Alternatives to Champions Oncology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Champions Oncology Inc News

Latest updates

Champions Oncology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	3.9%	12,019,000	11,573,000	12,561,000	13,071,000	12,773,000	14,281,000	13,745,000	12,877,000	13,193,000	11,786,000	11,253,000	10,564,000	10,812,000	10,117,000	9,547,000	8,748,500	9,012,000	7,625,000	6,737,000	7,719,000	6,430,000
Operating Expenses	7.9%	14,596,000	13,528,000	15,113,000	15,592,000	15,231,000	14,274,000	14,029,000	13,188,000	12,363,000	11,523,000	11,428,000	11,211,500	9,830,000	10,110,000	9,523,000	10,779,000	8,579,000	7,334,000	7,351,000	7,835,000	6,800,000
S&GA Expenses	0.1%	1,797,000	1,795,000	1,696,000	1,849,000	1,761,000	1,700,000	1,692,000	1,615,500	1,549,000	1,640,000	1,574,000	1,472,000	1,492,000	1,348,000	1,208,000	1,087,500	1,307,000	977,000	870,000	918,500	879,000
R&D Expenses	-13.1%	2,186,000	2,515,000	2,793,000	2,852,000	3,202,000	2,604,000	2,887,000	2,590,500	2,181,000	2,299,000	2,304,000	2,070,500	1,879,000	1,650,000	1,597,000	1,818,000	1,391,000	1,341,000	1,303,000	1,248,000	1,269,000
EBITDA Margin	-4.1%	-0.16	-0.15	-0.10	-0.06	-0.02	0.04	0.04	0.05	0.04	0.04	0.03	0.04	0.00	-	-	-	-	-	-	-	-
Income Taxes	0%	11,000	11,000	28,000	20,000	17,000	14,000	17,000	-2,000	11,000	12,000	14,000	32,000	15,000	15,000	13,000	92,000	12,000	11,000	15,000	102,500	-
Earnings Before Taxes	-22.3%	-2,519,000	-2,060,000	-2,538,000	-2,541,000	-2,422,000	-2,000	-302,000	-346,000	798,000	289,000	-158,000	-641,000	974,000	16,000	88,000	-2,073,500	419,000	318,000	-626,000	-150,000	-369,000
EBT Margin	-2.6%	-0.20	-0.19	-0.14	-0.10	-0.06	0.00	0.01	0.01	0.01	0.01	0.00	0.01	-0.03	-	-	-	-	-	-	-	-
Net Income	-22.2%	-2,530,000	-2,071,000	-2,566,000	-2,561,000	-2,439,000	-16,000	-319,000	-344,000	787,000	277,000	-172,000	-673,000	959,000	1,000	75,000	-1,999,500	75,000	307,000	-641,000	-253,000	-369,000
Net Income Margin	-2.5%	-0.20	-0.19	-0.14	-0.10	-0.06	0.00	0.01	0.01	0.00	0.01	0.00	0.01	-0.02	-	-	-	-	-	-	-	-
Free Cashflow	-339.7%	-1,045,000	436,000	-4,668,000	-1,452,000	819,000	2,682,000	-949,000	290,000	3,852,000	662,000	-691,000	-2,834,000	-1,068,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.3%	27.00	28.00	30.00	34.00	36.00	36.00	34.00	35.00	34.00	29.00	28.00	28.00	25.00	26.00	23.00	21.00	15.00	14.00	13.00	11.00	11.00
Current Assets	-5.8%	13.00	14.00	15.00	19.00	20.00	21.00	18.00	20.00	18.00	14.00	13.00	13.00	14.00	15.00	12.00	13.00	8.00	7.00	6.00	8.00	8.00
Cash Equivalents	-19.0%	4.00	6.00	5.00	10.00	12.00	11.00	8.00	9.00	9.00	5.00	4.00	5.00	7.00	9.00	7.00	8.00	3.00	3.00	2.00	3.00	3.00
Net PPE	-	-	-	-	-	-	8.00	8.00	7.00	7.00	7.00	7.00	6.00	6.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00
Liabilities	2.3%	29.00	28.00	28.00	30.00	29.00	27.00	25.00	26.00	24.00	21.00	21.00	20.00	17.00	19.00	17.00	16.00	12.00	12.00	12.00	9.00	9.00
Current Liabilities	4.9%	22.00	21.00	20.00	22.00	21.00	19.00	17.00	17.00	15.00	12.00	12.00	11.00	11.00	13.00	11.00	12.00	8.00	8.00	8.00	8.00	8.00
Shareholder's Equity	-2312.9%	-2.06	0.00	2.00	5.00	7.00	9.00	9.00	9.00	9.00	8.00	8.00	7.00	8.00	7.00	6.00	5.00	6.00	2.00	2.00	2.00	2.00
Retained Earnings	-3.0%	-84.50	-82.00	-79.88	-77.32	-74.80	-72.32	-72.30	-71.98	-71.60	-72.42	-72.70	-72.53	-71.64	-72.60	-72.60	-72.89	-70.62	-71.00	-71.30	-70.70	-70.40
Additional Paid-In Capital	0.5%	83.00	83.00	82.00	82.00	82.00	81.00	81.00	81.00	81.00	80.00	80.00	80.00	80.00	79.00	78.00	78.00	74.00	73.00	73.00	73.00	73.00
Shares Outstanding	0%	14.00	14.00	13.00	14.00	14.00	14.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	28.00	-	-	-	44.00	-	-	-	50.00	-	-	-	31.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-256.0%	-919	589	-3,991	-692	1,573	3,286	-195	796	4,257	1,228	216	-1,980	135	879	-715	2,545	279	360	-279	252	1,210
Share Based Compensation	615.1%	379	53.00	423	208	331	119	206	188	310	134	280	161	232	85.00	120	163	229	77.00	131	138	335
Cashflow From Investing	17.6%	-126	-153	-668	-760	-754	-604	-754	-506	-405	-566	-907	-834	-1,203	-506	-626	-1,527	-171	227	-749	-141	-207
Cashflow From Financing	-100.0%	-	208	-590	-75.00	-	86.00	-	16.00	68.00	121	2.00	72.00	-56.00	1,237	-58.00	4,042	390	-5.00	-7.00	-184	351
Buy Backs	-100.0%	-	32.00	602	74.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

CSBR Income Statement

2024-01-31

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Oncology services revenue	$ 12,019	$ 12,773	$ 36,153	$ 40,799
Costs and operating expenses:
Cost, Product and Service [Extensible List]	Service [Member]	Service [Member]	Service [Member]	Service [Member]
Cost of oncology services	$ 7,849	$ 7,699	$ 22,151	$ 22,194
Research and development	2,186	3,202	7,494	8,693
Sales and marketing	1,797	1,761	5,288	5,153
General and administrative	2,764	2,569	8,305	7,494
Total costs and operating expenses	14,596	15,231	43,238	43,534
Loss from operations	(2,577)	(2,458)	(7,085)	(2,735)
Other income (loss)	58	36	(33)	9
Loss before provision for income taxes	(2,519)	(2,422)	(7,118)	(2,726)
Provision for income taxes	11	17	49	48
Net loss	$ (2,530)	$ (2,439)	$ (7,167)	$ (2,774)
Net loss per common share outstanding
Basic (in dollars per share)	$ (0.19)	$ (0.18)	$ (0.53)	$ (0.20)
Diluted (in dollars per share)	$ (0.19)	$ (0.18)	$ (0.53)	$ (0.20)
Weighted average common shares outstanding
Basic (in shares)	13,593,758	13,558,642	13,538,480	13,532,990
Diluted (in shares)	13,593,758	13,558,642	13,538,480	13,532,990

CSBR Balance Sheet

2024-01-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2024	Apr. 30, 2023
Current assets:
Cash and cash equivalents	$ 4,468	$ 10,118
Accounts receivable, net	7,895	8,011
Prepaid expenses and other current assets	835	1,328
Total current assets	13,198	19,457
Operating lease right-of-use assets, net	6,536	7,318
Property and equipment, net	6,533	7,186
Other long-term assets	185	15
Goodwill	335	335
Total assets	26,787	34,311
Current liabilities:
Accounts payable	4,756	5,334
Accrued liabilities	2,430	2,270
Current portion of operating lease liabilities	1,305	1,208
Other current liability	149	145
Deferred revenue	13,329	12,776
Total current liabilities	21,969	21,733
Non-current operating lease liabilities	6,437	7,391
Other non-current liabilities	439	551
Total liabilities	28,845	29,675
Stockholders’ equity (deficiency):
Common stock, $.001 par value; 200,000,000 shares authorized; 13,714,099 and 13,558,650 shares issued; and 13,593,766 and 13,544,228 outstanding as of January 31, 2024 and April 30, 2023, respectively	14	14
Treasury stock, at cost	(708)	(74)
Additional paid-in capital	83,120	82,013
Accumulated deficit	(84,484)	(77,317)
Total stockholders’ equity (deficiency)	(2,058)	4,636
Total liabilities and stockholders’ equity (deficiency)	$ 26,787	$ 34,311

About Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a dynamic analytic and visualization software that empowers cancer biologists to harness the power of computational science in a convenient and sophisticated tool. The company markets its products through internet, word of mouth, and sales force to patients and physicians. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

CEO	Dr. Ronnie Morris M.D.
WEBSITE	championsoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	230

Champions Oncology Inc Frequently Asked Questions

What is the ticker symbol for Champions Oncology Inc? What does CSBR stand for in stocks?

CSBR is the stock ticker symbol of Champions Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Champions Oncology Inc (CSBR)?

As of Fri Apr 19 2024, market cap of Champions Oncology Inc is 68.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CSBR stock?

You can check CSBR's fair value in chart for subscribers.

What is the fair value of CSBR stock?

You can check CSBR's fair value in chart for subscribers. The fair value of Champions Oncology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Champions Oncology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CSBR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Champions Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether CSBR is over valued or under valued. Whether Champions Oncology Inc is cheap or expensive depends on the assumptions which impact Champions Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CSBR.

What is Champions Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CSBR's PE ratio (Price to Earnings) is -7.07 and Price to Sales (PS) ratio is 1.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSBR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Champions Oncology Inc's stock?

In the past 10 years, Champions Oncology Inc has provided 0.188 (multiply by 100 for percentage) rate of return.